- ISIN
- BMG889121031
- CUSIP
- 88875G101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 24, 2000
Highlights
- Market Cap
- $68.39M
- Enterprise Value
- $65.06M
- EPS (TTM)
- -$0.59
- Gross Profit (TTM)
- -$421.00K
- EBITDA (TTM)
- -$42.26M
- Year Range
- $1.04 - $2.60
- ROA (TTM)
- -304.03%
- ROE (TTM)
- -67,207.69%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TLSA Performance Chart
Tiziana Life Sciences PLC (TLSA) is down 22.8% since the beginning of the year. At $1 per share, TLSA is trading 55.8% below its 52-week high of $3. Investors who bought $1,000 worth of TLSA shares 5 years ago would now be looking at an investment worth $477.
Loading charts...
Returns By Period
Tiziana Life Sciences PLC (TLSA) has returned -22.82% so far this year and -26.28% over the past 12 months.
Tiziana Life Sciences PLC
- 1D
- -0.86%
- 1M
- -22.30%
- YTD
- -22.82%
- 6M
- -25.32%
- 1Y
- -26.28%
- 3Y*
- 16.89%
- 5Y*
- -13.75%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
TLSA Monthly Returns History
Based on dividend-adjusted daily data since Nov 20, 2018, TLSA's average daily return is +0.20%, while the average monthly return is +3.23%. At this rate, an investment would double in approximately 1.8 years.
Historically, 33% of months were positive and 67% were negative. The best month was Jul 2020 with a return of +172.1%, while the worst month was Aug 2020 at -49.5%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 8 months.
On a daily basis, TLSA closed higher 44% of trading days. The best single day was Mar 11, 2020 with a return of +95.5%, while the worst single day was Mar 13, 2020 at -36.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.34% | -3.97% | -19.31% | 9.40% | 10.16% | -18.44% | -22.82% | ||||||
| 2025 | -1.61% | 88.32% | -16.28% | 25.93% | 0.00% | 16.18% | 58.23% | -27.60% | 19.34% | -11.11% | -6.25% | -17.22% | 114.02% |
| 2024 | -5.18% | -9.49% | -5.53% | 44.66% | 52.25% | -8.09% | 16.43% | -6.54% | -4.00% | 1.56% | -2.56% | -26.72% | 24.32% |
| 2023 | 7.77% | -13.63% | 95.94% | -28.08% | 8.28% | -19.84% | -4.61% | 11.85% | -9.23% | -0.86% | -9.81% | -5.08% | -6.43% |
| 2022 | -13.54% | -21.67% | 61.51% | -2.86% | -34.85% | 12.19% | -1.92% | 4.32% | 2.25% | -10.90% | -5.28% | -9.08% | -37.66% |
| 2021 | 82.18% | -18.21% | -7.97% | -5.78% | -9.96% | -0.21% | -9.17% | -22.07% | -12.05% | 6.85% | -19.23% | -23.81% | -52.48% |
Benchmark Metrics
Tiziana Life Sciences PLC has an annualized alpha of 58.20%, beta of 0.34, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since November 20, 2018.
- This stock participated in 52.73% of S&P 500 Index downside but only 0.94% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.34 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 58.20%
- Beta
- 0.34
- R²
- 0.00
- Upside Capture
- 0.94%
- Downside Capture
- 52.73%
Return for Risk
Risk / Return Rank
TLSA ranks 29 for risk / return — below 29% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tiziana Life Sciences PLC (TLSA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TLSA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.36 | ||
| Sortino ratioReturn per unit of downside risk | -2.75 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.46 | 2.78 | -3.25 |
| Martin ratioReturn relative to average drawdown | -0.73 | 12.44 | -13.17 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tiziana Life Sciences PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tiziana Life Sciences PLC was 94.03%, occurring on Mar 27, 2024. The portfolio has not yet recovered.
The current Tiziana Life Sciences PLC drawdown is 83.55%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -94.03%Mar 2024 | 3y 7mo | — | 5y 10moAug 2020 - now |
COVID crash2020 | -68.27%Feb 2020 | 1y 3mo | 2mo 21d | 1y 5moNov 2018 - May 2020 |
2020 bear market2020 | -28.10%Jul 2020 | 2d | 7d | 9dJul 2020 - Jul 2020 |
2020 bear market2020 | -21.46%Jun 2020 | 9d | 25d | 1mo 4dJun 2020 - Jul 2020 |
Rate-hike selloffLate 2018 | -20.48%Nov 2018 | 0s | 1d | 1dNov 2018 - Nov 2018 |
Drawdown Indicators
| TLSA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.03% | -56.78% | -37.25% |
Max Drawdown (1Y)Largest decline over 1 year | -56.80% | -9.10% | -47.70% |
Max Drawdown (3Y)Largest decline over 3 years | -56.80% | -18.90% | -37.90% |
Max Drawdown (5Y)Largest decline over 5 years | -83.32% | -25.43% | -57.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -83.55% | -1.80% | -81.75% |
Average DrawdownAverage peak-to-trough decline | -70.34% | -10.71% | -59.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.04% | 2.03% | +34.01% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tiziana Life Sciences PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tiziana Life Sciences PLC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TLSA in comparison with other companies in the Biotechnology industry. Currently, TLSA has a P/B value of 1,315.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TLSA
Add Tiziana Life Sciences PLC to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TLSA